• By Terri Malloy

Physicians, scientists and physician-scientists connect dots between heart disease, potential for worse COVID-19 outcomes

April 27, 2020
two Caucasian women in white lab coats, perhaps researchers, reviewing medical and scientific data on a computer screen

ROCHESTER, Minn. ― People with certain heart diseases may be more susceptible to worse outcomes with COVID-19, but the reason why has remained unknown. New research from Mayo Clinic indicates that in patients with one specific type of heart disease ― obstructive hypertrophic cardiomyopathy (HCM) ― the heart increases production of the ACE2 RNA transcript and the translated ACE2 protein.

Normally, this pathological response at the cellular level might be the heart's attempt to compensate for changes caused by disease. Unfortunately, SARS-CoV-2, the virus that causes COVID-19, hijacks these ACE2 receptors on the membrane of cells and uses them to get inside the cells. The virus not only gains entry through ACE2, but also it takes this protein with it, removing a protective signaling pathway that normally counters the negative impact of the hormone angiotensin II. This hormone increases blood pressure and leads to fluid retention.

Over the course of a nearly 20-year study published in Mayo Clinic Proceedings, researchers analyzed frozen samples of heart muscle tissue from 106 patients who had surgery for obstructive hypertrophic cardiomyopathy. The control group used heart tissue from 39 healthy donor hearts.

"Of all the RNA transcripts in the entire human genome, our research revealed that the single most upregulated RNA transcript in the heart muscle was ACE2. In fact, we confirmed a fivefold increase in ACE2 protein levels in the heart muscle of these patients with obstructive HCM," says Michael Ackerman, M.D., Ph.D., a genetic cardiologist at Mayo Clinic. "This could connect the dots and potentially explain why patients with certain heart diseases might fare worse with COVID-19."

Dr. Ackerman is director of the Windland Smith Rice Sudden Death Genomics Laboratory at Mayo Clinic and senior author on the study. This study involved national and international investigators.

The next step is to look for other elevated ACE2 levels by analyzing available heart tissue from patients who have died from hypertension and other heart diseases. Lung tissue from COVID-19 victims also could be analyzed to see if ACE2 levels are higher than in normal lung tissue.

"This discovery provides another reason for patients taking angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers to stay on their heart medications, as recommended by all major cardiac societies," says Dr. Ackerman. "Removing these medications in a patient whose heart has elevated protein levels of ACE2 could cause even more tissue damage."

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news and An Inside Look at Mayo Clinic for more information about Mayo.

About Mayo Clinic Proceedings
Mayo Clinic Proceedings is a monthly peer-reviewed medical journal that publishes original articles and reviews dealing with clinical and laboratory medicine, clinical research, basic science research, and clinical epidemiology. Mayo Clinic Proceedings is sponsored by the Mayo Foundation for Medical Education and Research as part of its commitment to physician education. It publishes submissions from authors worldwide. The journal has been published for more than 90 years and has a circulation of 127,000.

Media contact:

Please login or register to post a reply.